The Experts below are selected from a list of 4269 Experts worldwide ranked by ideXlab platform

Thomas R. Spitzer - One of the best experts on this subject based on the ideXlab platform.

  • hematopoietic stem cell transplant associated Thrombotic Microangiopathy current paradigm and novel therapies
    Bone Marrow Transplantation, 2018
    Co-Authors: J Khosla, Thomas R. Spitzer
    Abstract:

    Hematopoietic stem cell transplant-associated Thrombotic Microangiopathy: current paradigm and novel therapies

  • hematopoietic stem cell transplant associated Thrombotic Microangiopathy current paradigm and novel therapies
    Bone Marrow Transplantation, 2018
    Co-Authors: J Khosla, Thomas R. Spitzer, Albert C Yeh, Bimalangshu R Dey
    Abstract:

    Hematopoietic stem cell transplantation-associated Thrombotic Microangiopathy (TA-TMA) remains a difficult complication to address due to its high mortality rate, lack of standard diagnostic criteria and limited therapeutic options. Underscoring this challenge is the complex pathophysiology involved and multiple contributing factors that converge on a final pathway involving widespread endothelial injury and complement activation. In addressing our current understanding of TA-TMA, we highlight the risk factors leading to endothelial damage and a pathophysiological cascade that ensues. We have also compared the different definition criteria and biomarkers that can enable early intervention in TA-TMA patients. Current first-line management includes discontinuation or alteration of the immunosuppressive regimen, treatment of co-existing infectious and GVHD, aggressive hypertension control and supportive therapy. We discuss current pharmacological therapies, including newer agents that target the complement cascade and nitric oxide pathways.

J Khosla - One of the best experts on this subject based on the ideXlab platform.

  • hematopoietic stem cell transplant associated Thrombotic Microangiopathy current paradigm and novel therapies
    Bone Marrow Transplantation, 2018
    Co-Authors: J Khosla, Thomas R. Spitzer
    Abstract:

    Hematopoietic stem cell transplant-associated Thrombotic Microangiopathy: current paradigm and novel therapies

  • hematopoietic stem cell transplant associated Thrombotic Microangiopathy current paradigm and novel therapies
    Bone Marrow Transplantation, 2018
    Co-Authors: J Khosla, Thomas R. Spitzer, Albert C Yeh, Bimalangshu R Dey
    Abstract:

    Hematopoietic stem cell transplantation-associated Thrombotic Microangiopathy (TA-TMA) remains a difficult complication to address due to its high mortality rate, lack of standard diagnostic criteria and limited therapeutic options. Underscoring this challenge is the complex pathophysiology involved and multiple contributing factors that converge on a final pathway involving widespread endothelial injury and complement activation. In addressing our current understanding of TA-TMA, we highlight the risk factors leading to endothelial damage and a pathophysiological cascade that ensues. We have also compared the different definition criteria and biomarkers that can enable early intervention in TA-TMA patients. Current first-line management includes discontinuation or alteration of the immunosuppressive regimen, treatment of co-existing infectious and GVHD, aggressive hypertension control and supportive therapy. We discuss current pharmacological therapies, including newer agents that target the complement cascade and nitric oxide pathways.

Charles L Bennett - One of the best experts on this subject based on the ideXlab platform.

  • drug induced Thrombotic Microangiopathy
    Seminars in Thrombosis and Hemostasis, 2005
    Co-Authors: Anaadriana Zakarija, Charles L Bennett
    Abstract:

    Drug-associated Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (TTP/HUS) has been recognized for several years. The most commonly implicated drugs are mitomycin-C, cyclosporine, quinine, and ticlopidine. As with idiopathic cases of TTP/HUS, basic science discoveries in the late 1990s now suggest that the likely mechanisms by which these agents lead to a Thrombotic Microangiopathy (TMA) include either an immune-mediated phenomenon involving the ADAMTS13 metalloprotease or direct endothelial toxicity. This article reviews the current understanding of the pathogenesis, the clinical and laboratory features, and the recommended treatments, prognosis, and outcomes of drug-associated TMA.

Bimalangshu R Dey - One of the best experts on this subject based on the ideXlab platform.

  • hematopoietic stem cell transplant associated Thrombotic Microangiopathy current paradigm and novel therapies
    Bone Marrow Transplantation, 2018
    Co-Authors: J Khosla, Thomas R. Spitzer, Albert C Yeh, Bimalangshu R Dey
    Abstract:

    Hematopoietic stem cell transplantation-associated Thrombotic Microangiopathy (TA-TMA) remains a difficult complication to address due to its high mortality rate, lack of standard diagnostic criteria and limited therapeutic options. Underscoring this challenge is the complex pathophysiology involved and multiple contributing factors that converge on a final pathway involving widespread endothelial injury and complement activation. In addressing our current understanding of TA-TMA, we highlight the risk factors leading to endothelial damage and a pathophysiological cascade that ensues. We have also compared the different definition criteria and biomarkers that can enable early intervention in TA-TMA patients. Current first-line management includes discontinuation or alteration of the immunosuppressive regimen, treatment of co-existing infectious and GVHD, aggressive hypertension control and supportive therapy. We discuss current pharmacological therapies, including newer agents that target the complement cascade and nitric oxide pathways.

Stephen J Wort - One of the best experts on this subject based on the ideXlab platform.

  • pulmonary tumour Thrombotic Microangiopathy
    Current Opinion in Pulmonary Medicine, 2016
    Co-Authors: Laura C Price, Athol U Wells, Stephen J Wort
    Abstract:

    Purpose of reviewPulmonary tumour Thrombotic Microangiopathy (PTTM) describes tumour cell microemboli with occlusive fibrointimal remodelling in small pulmonary arteries, veins and lymphatics. Progressive vessel occlusion ultimately results in pulmonary hypertension, which is often severe and rapid